Kim, Sang T.
Bittar, Mohamad
Kim, Hyun J.
Neelapu, Sattva S.
Zurita, Amado J.
Nurieva, Roza
Suarez-Almazor, Maria E.
Funding for this research was provided by:
University of Texas MD Anderson Cancer Center (Division of Internal Medicine Developmental Funds, Moon Shots Program)
National Cancer Institute (R03CA219760)
Article History
Received: 11 December 2018
Accepted: 22 April 2019
First Online: 14 May 2019
Ethics approval and consent to participate
: Synovial fluid collection for the study was approved by an Institutional Review Board at the University of Texas MD Anderson Cancer Center (IRB #: PA16-0935). The patient signed consent allowing use of his biospecimens.
: Obtained.
: Dr. Neelapu has received research support from Kite/Gilead, Celgene, Cellectis, Poseida, Merck, Acerta, Karus, and BMS; served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, and Merck. Dr. Suarez-Almazor has received consultant fees from Pfizer, Eli Lilly, AbbVie and Bristol Myers Squibb unrelated to this work. Dr. Nurieva is a consultant for Nurix, Inc. studies that are not related to this work. Other authors declared no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.